Iambic releases next version of its Enchant model, signs deal with AbbVie
Iambic launched Enchant v3, a 41-billion-parameter AI model, and signed an R&D deal with AbbVie covering small molecules in immunology, neuroscience and oncology.
Iambic Therapeutics
Private
AI-driven small molecule drug discovery company whose Enchant platform combines generative models such as NeuralPLexer with high-throughput experimentation to design therapeutics; partnered with AbbVie and Revolution Medicines.
Company Info
Sector:AI Drug Discovery
Headquarters:San Diego, California, USA
Founded:2019
Website:www.iambic.ai/
Funding Round:Series B
Total Funding:~$150M
Upcoming Milestones & Key Dates
2026
Partnership
AbbVie R&D collaboration on Enchant v3-discovered small molecules
Clinical Development Pipeline
Enchant (AI discovery platform)
Target: AI/ML generative platformIAM1363
Target: HER2Recent News
Leadership Team
Tom Miller
Co-Founder and Chief Executive Officer
Fred Manby
Co-Founder and Chief Technology Officer
Neil Josephson
Chief Medical Officer